The Octopus Value Investing logo
The Octopus Value Investing
Subscribe
  • The Octopus Value Investing
  • Topics
  • Novo Nordisk

Novo Nordisk

Newsletter covering Novo Nordisk

News & Trending TopicsTheon InternationalPandoraThe Octopus toolboxLonza Group AGIntroductionMiscellaneousThe Octopus PortfolioColoplast A/SSectors in briefInvestment pillsSchott Pharma AGJeronimo MartinsEarnings ReviewNovo Nordisk
MiscellaneousMiscellaneous
+1+1
#2 Investment Sidebar Snapshots
Jul 13, 2025

#2 Investment Sidebar Snapshots

Compiling One Month of Novo Nordisk News & Updates

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk - Q1 2025 Earnings Review
May 11, 2025

Novo Nordisk - Q1 2025 Earnings Review

When Expectations Are So Low...

The Octopus Value Investing
The Octopus Value Investing
Novo NordiskNovo Nordisk
Novo Nordisk Valuation Update
May 01, 2025

Novo Nordisk Valuation Update

The Margin of Safety Might Have Never Been Larger

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk A/S - 2024 Earnings Review
Feb 09, 2025

Novo Nordisk A/S - 2024 Earnings Review

When Expectations Are So Low Tha

The Octopus Value Investing
The Octopus Value Investing
News & Trending TopicsNews & Trending Topics
+1+1
CagriSema Phase III Results Review
Dec 22, 2024

CagriSema Phase III Results Review

Novo Nordisk Stock Plunge: Overreaction or Justified?

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+3+3
Q3 2024 Earnings Recap
Nov 10, 2024

Q3 2024 Earnings Recap

Earnings Review Compilation of Novo Nordisk, Pandora & Lonza AG

The Octopus Value Investing
The Octopus Value Investing
News & Trending TopicsNews & Trending Topics
+1+1
Novo Nordisk September 2024 recap
Sep 29, 2024

Novo Nordisk September 2024 recap

An hectic month for the Danish company

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
+1+1
Understanding NASH/MASH
Sep 08, 2024

Understanding NASH/MASH

Uncovering the potential behind Novo Nordisk's optionality

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk - H1 2024 Earnings review
Aug 13, 2024

Novo Nordisk - H1 2024 Earnings review

More leader in the GLP-1 space than ever

The Octopus Value Investing
The Octopus Value Investing
Novo NordiskNovo Nordisk
#3 The Octopus Toolbox - The Novo Nordisk Report
Jul 21, 2024

#3 The Octopus Toolbox - The Novo Nordisk Report

My podcast with MDBolsa in writing

The Octopus Value Investing
The Octopus Value Investing
News & Trending TopicsNews & Trending Topics
+2+2
Novo Nordisk - 2023 Earnings Review
Feb 04, 2024

Novo Nordisk - 2023 Earnings Review

The GLP-1 growth engine keeps working like a clockwork

The Octopus Value Investing
The Octopus Value Investing
Novo NordiskNovo Nordisk
#5 Novo Nordisk - The Other Side of the Story
Dec 17, 2023

#5 Novo Nordisk - The Other Side of the Story

Uncovering the potential weaknesess on the GLP-1 leader thesis

The Octopus Value Investing
The Octopus Value Investing

The Octopus Value Investing

Home

Posts

Authors

© 2025 The Octopus Value Investing.

Privacy policy

Terms of use

Powered by beehiiv